Squalene Epoxidase and Breast Cancer Outcomes
Author Information
Author(s): Helms M W, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E, Liedtke C, Schlotter C M, Wang A, Chan S Y, Brandt B H
Primary Institution: Stanford University School of Medicine
Hypothesis
Does squalene epoxidase (SQLE) expression indicate poor clinical outcomes in stage I and II breast cancer?
Conclusion
Higher levels of SQLE mRNA expression are associated with a significantly increased risk of distant metastasis in ER+ stage I/II breast cancer patients.
Supporting Evidence
- High SQLE expression was associated with a 5-year distant metastasis-free survival rate of only 16%.
- Patients with low SQLE expression had a 30% better estimate of distant metastasis-free survival compared to those with high expression.
- Multivariate analysis indicated that SQLE expression is an independent risk factor for metastatic relapse.
Takeaway
This study found that a protein called squalene epoxidase can help doctors figure out which breast cancer patients are at higher risk of their cancer coming back.
Methodology
The study used suppression subtractive hybridization and real-time RT-PCR to analyze mRNA expression in breast cancer tissues from 186 patients.
Potential Biases
Potential biases may arise from the selection of patient cohorts and the retrospective nature of the analysis.
Limitations
The study's findings may not be generalizable to all breast cancer patients, as it focused on a specific subtype.
Participant Demographics
The mean age of participants was 58 years, with 68.7% older than 55 years; most tumors were of medium (41% G2) and high grades (34% G3).
Statistical Information
P-Value
0.0014
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website